Karl-Erik Andersson

List of Publications by Year in Descending Order

131 papers	3,369 citations	29 h-index	55 g-index
138 ext. papers	3,851 ext. citations	4.1 avg, IF	5.97 L-index

#	Paper	IF	Citations
131	Treatment of Stress Urinary Incontinence with Muscle Stem Cells and Stem Cell Components: Chances, Challenges and Future Prospects. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
130	Gene Therapy for Overactive Bladder: A Review of BK-Channel β-Subunit Gene Transfer. *Therapeutics and Clinical Risk Management*, **2021**, 17, 589-599	2.9	2
129	Re: Systemic Therapy for Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC): Systematic Review of Published Trials in the Last 5 Years. *European Urology*, **2021**, 79, 431-432	10.2	
128	Best practices for cystometric evaluation of lower urinary tract function in muriform rodents. *Neurourology and Urodynamics*, **2020**, 39, 1868-1884	2.3	10
127	Are oxidative stress and ischemia significant causes of bladder damage leading to lower urinary tract dysfunction? Report from the ICI-RS 2019. *Neurourology and Urodynamics*, **2020**, 39 Suppl 3, S16-S22	2.3	11
126	Incontinence in Patients With Underactive Bladder. *International Neurourology Journal*, **2020**, 24, 293-294	1.6	
125	Are there relevant animal models to set research priorities in LUTD? ICI-RS 2019. *Neurourology and Urodynamics*, **2020**, 39 Suppl 3, S9-S15	2.3	0
124	Gene Therapy in Erectile Dysfunction: Dead or Alive?. *Journal of Sexual Medicine*, **2020**, 17, 1587-1589	1.1	0
123	Evaluating the safety and potential activity of URO-902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. *Neurourology and Urodynamics*, **2020**, 39, 744-753	2.3	13
122	Liquid chromatography-mass spectrometry identification of serum biomarkers for nocturia in aged men. *World Journal of Urology*, **2019**, 37, 2199-2205	4	2
121	Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects. *Pharmaceutical Research*, **2019**, 36, 92	4.5	3
120	TRP Channels as Lower Urinary Tract Sensory Targets. *Medical Sciences (Basel, Switzerland)*, **2019**, 7,	3.3	16
119	Streptozotocin-induced diabetes causes upregulation of serotonin (5-HT) receptors in lumbosacral cord motoneurons and down regulation of serotonergic paraneurons in the urethra. *Brain Research*, **2019**, 1715, 21-26	3.7	3
118	The serotonin (5-hydroxytryptamine) 5-HT receptor is up-regulated in Onuf's nucleus in rats with chronic spinal cord injury. *BJU International*, **2019**, 123, 718-725	5.6	5
117	Extended periprostatic nerve distributions on the prostate surface confirmed using diffusion tensor imaging. *BJU International*, **2019**, 123, 995-1004	5.6	7
116	Agents in early development for treatment of bladder dysfunction - promise of drugs acting at TRP channels?. *Expert Opinion on Investigational Drugs*, **2019**, 28, 749-755	5.9	10
115	Future Considerations in Overactive Bladder Pharmacotherapy **2019**, 219-229		1

114	Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. *European Urology*, **2019**, 75, 129-168	10.2	12
113	Current concepts of the acontractile bladder. *BJU International*, **2018**, 122, 195-202	5.6	5
112	Chronic spinal cord injury causes upregulation of serotonin (5-HT) and 5-HT receptors in lumbosacral cord motoneurons. *BJU International*, **2018**, 121, 145-154	5.6	3
111	Oxidative stress and its possible relation to lower urinary tract functional pathology. *BJU International*, **2018**, 121, 527-533	5.6	20
110	Development of contractile properties in the fetal porcine urinary bladder. *Pediatric Research*, **2018**, 83, 148-155	3.2	1
109	Increased autophagy contributes to impaired smooth muscle function in neurogenic lower urinary tract dysfunction. *Neurourology and Urodynamics*, **2018**, 37, 2414-2424	2.3	3
108	Animal Modelling of Interstitial Cystitis/Bladder Pain Syndrome. *International Neurourology Journal*, **2018**, 22, S3-9	2.6	34
107	The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy. *Therapeutic Advances in Urology*, **2018**, 10, 243-256	3.2	9
106	Neuroepithelial control of mucosal inflammation in acute cystitis. *Scientific Reports*, **2018**, 8, 11015	4.9	16
105	Which molecular targets do we need to focus on to improve lower urinary tract dysfunction? ICI-RS 2017. *Neurourology and Urodynamics*, **2018**, 37, S117-S126	2.3	9
104	Fibrosis and the bladder, implications for function ICI-RS 2017. *Neurourology and Urodynamics*, **2018**, 37, S7-S12	2.3	19
103	Cell Versus Chemokine Therapy Effects on Cell Mobilization to Chronically Dysfunctional Urinary Sphincters of Nonhuman Primates. *International Neurourology Journal*, **2018**, 22, 260-267	2.6	3
102	Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2018**, 70, 570-578	4.4	8
101	Nonhuman primate model of persistent erectile and urinary dysfunction following radical prostatectomy: Feasibility of minimally invasive therapy. *Neurourology and Urodynamics*, **2018**, 37, 2141-2150	2.3	8
100	Bladder Capacity is a Biomarker for a Bladder Centric versus Systemic Manifestation in Interstitial Cystitis/Bladder Pain Syndrome. *Journal of Urology*, **2017**, 198, 369-375	2.5	24
99	Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain. *Pain*, **2017**, 158, 1538-1545	8	11
98	Can incontinence be cured? A systematic review of cure rates. *BMC Medicine*, **2017**, 15, 63	11.4	38
97	Current Pharmacologic Approaches in Painful Bladder Research: An Update. *International Neurourology Journal*, **2017**, 21, 235-242	2.6	16

96	Efficacy and Initial Safety Profile of CXCL12 Treatment in a Rodent Model of Urinary Sphincter Deficiency. *Stem Cells Translational Medicine*, **2017**, 6, 1740-1746	6.9	7
95	Characteristics of the mechanosensitive bladder afferent activities in relation with microcontractions in male rats with bladder outlet obstruction. *Scientific Reports*, **2017**, 7, 7646	4.9	7
94	Evaluating the Procedure for Performing Awake Cystometry in a Mouse Model. *Journal of Visualized Experiments*, **2017**,	1.6	5
93	Re: Inhibition of Cholinergic Neurotransmission by □adrenoceptors Depends on Adenosine Release and A Receptors Activation in Human and Rat Urinary Bladders. *European Urology*, **2017**, 72, 650-651	10.2	
92	Determinates of muscle precursor cell therapy efficacy in a nonhuman primate model of intrinsic urinary sphincter deficiency. *Stem Cell Research and Therapy*, **2017**, 8, 1	8.3	64
91	Erectile Dysfunction and Lower Urinary Tract Symptoms. *European Urology Focus*, **2017**, 3, 352-363	5.1	41
90	Association of lower urinary tract syndrome with peripheral arterial occlusive disease. *PLoS ONE*, **2017**, 12, e0170288	3.7	13
89	On the Site and Mechanism of Action of □Adrenoceptor Agonists in the Bladder. *International Neurourology Journal*, **2017**, 21, 6-11	2.6	27
88	Characterization of a Murine Model of Bioequivalent Bladder Wound Healing and Repair Following Subtotal Cystectomy. *BioResearch Open Access*, **2017**, 6, 35-45	2.4	
87	Regenerative Medicine Therapies for Stress Urinary Incontinence. *Journal of Urology*, **2016**, 196, 1619-1626	2.5	21
86	Re: Nonantimuscarinic Treatment for Overactive Bladder: A Systematic Review. *European Urology*, **2016**, 70, 1077	10.2	
85	Local versus intravenous injections of skeletal muscle precursor cells in nonhuman primates with acute or chronic intrinsic urinary sphincter deficiency. *Stem Cell Research and Therapy*, **2016**, 7, 147	8.3	10
84	Preventive Effects of Long-Term Caloric Restriction on Aging Related In□Vivo Bladder Dysfunction and Molecular Biological Changes in the Bladder and Dorsal Root Ganglia in Rats. *Journal of Urology* , **2016**, 196, 1575-1583	2.5	9
83	Sensitivity to the thromboxane A2 analog U46619 varies with inner diameter in human stem villous arteries. *Placenta*, **2016**, 39, 111-5	3.4	3
82	Tramadol Abuse and Sexual Function. *Sexual Medicine Reviews*, **2016**, 4, 235-246	5.6	30
81	Pharmacology: On the mode of action of mirabegron. *Nature Reviews Urology*, **2016**, 13, 131-2	5.5	11
80	Regenerative pharmacology: recent developments and future perspectives. *Regenerative Medicine*, **2016**, 11, 859-870	2.5	4
79	Melatonin Improves Erectile Function in Rats With Chronic Lower Body Ischemia. *Journal of Sexual Medicine*, **2016**, 13, 179-86	1.1	4

78	Cell versus Chemokine Therapy in a Nonhuman Primate Model of Chronic Intrinsic Urinary Sphincter Deficiency. *Journal of Urology*, **2016**, 196, 1809-1815	2.5	14
77	Fundamentals and clinical perspective of urethral sphincter instability as a contributing factor in patients with lower urinary tract dysfunction--ICI-RS 2014. *Neurourology and Urodynamics*, **2016**, 35, 318-23	2.3	19
76	Potential Future Pharmacological Treatment of Bladder Dysfunction. *Basic and Clinical Pharmacology and Toxicology*, **2016**, 119 Suppl 3, 75-85	3.1	51
75	Differentiated adipose-derived stem cells for bladder bioengineering. *Scandinavian Journal of Urology*, **2015**, 49, 407-14	1.6	13
74	Potential of stem cell treatment in detrusor dysfunction. *Advanced Drug Delivery Reviews*, **2015**, 82-83, 117-22	18.5	7
73	Intraprostatic injections for lower urinary tract symptoms treatment. *Current Opinion in Urology*, **2015**, 25, 12-8	2.8	9
72	Promising experimental drugs and drug targets **2015**, 100-117		
71	The potential utility of non-invasive imaging to monitor restoration of bladder structure and function following subtotal cystectomy (STC). *BMC Urology*, **2015**, 15, 103	2.2	1
70	Serotonin (5-HT)2A/2C receptor agonist (2,5-dimethoxy-4-idophenyl)-2-aminopropane hydrochloride (DOI) improves voiding efficiency in the diabetic rat. *BJU International*, **2015**, 116, 147-55	5.6	9
69	Drug therapy of overactive bladder--what is coming next?. *Korean Journal of Urology*, **2015**, 56, 673-9		5
68	Superoxide overproduction and kidney fibrosis: a new animal model. *Einstein (Sao Paulo, Brazil)*, **2015**, 13, 79-88	1.2	6
67	Chronic Pelvic Ischemia: Contribution to the Pathogenesis of Lower Urinary Tract Symptoms (LUTS): A New Target for Pharmacological Treatment?. *LUTS: Lower Urinary Tract Symptoms*, **2015**, 7, 1-8	1.9	26
66	Translational Research and Functional Changes in Voiding Function in Older Adults. *Clinics in Geriatric Medicine*, **2015**, 31, 535-48	3.8	13
65	Effects of allogeneic bone marrow derived mesenchymal stromal cell therapy on voiding function in a rat model of Parkinson disease. *Journal of Urology*, **2014**, 191, 850-9	2.5	16
64	Calcium signalling in Cajal-like interstitial cells of the lower urinary tract. *Nature Reviews Urology*, **2014**, 11, 555-64	5.5	29
63	Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome. *Journal of Urology*, **2014**, 192, 1123-9	2.5	34
62	Transcriptome analysis of bladder biopsy from interstitial cystitis/bladder pain syndrome patients. *Genomics Data*, **2014**, 2, 366-8		2
61	Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate. *American Journal of Physiology - Renal Physiology*, **2014**, 307, F823-32	4.3	18

60	The use of pharmacotherapy for male patients with urgency and stress incontinence. *Current Opinion in Urology*, **2014**, 24, 571-7	2.8	7
59	The many faces of impaired bladder emptying. *Current Opinion in Urology*, **2014**, 24, 363-9	2.8	30
58	Progressive vascular damage may lead to bladder underactivity in rats. *Journal of Urology*, **2014**, 191, 1462-9	2.5	50
57	Lamina propria: the functional center of the bladder?. *Neurourology and Urodynamics*, **2014**, 33, 9-16	2.3	93
56	β-receptor agonists for overactive bladder--new frontier or more of the same?. *Current Urology Reports*, **2013**, 14, 435-41	2.9	7
55	Treatment of lower urinary tract symptoms: agents for intraprostatic injection. *Scandinavian Journal of Urology*, **2013**, 47, 83-90	1.6	12
54	Age-related alterations in regeneration of the urinary bladder after subtotal cystectomy. *American Journal of Pathology*, **2013**, 183, 1585-1595	5.8	9
53	The novel β-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. *European Journal of Pharmacology*, **2013**, 699, 101-5	5.3	34
52	Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. *International Journal of Urology*, **2013**, 20, 21-7	2.3	24
51	Selective βadrenoceptor agonists for the treatment of overactive bladder. *Journal of Urology*, **2013**, 190, 1173-80	2.5	58
50	Future therapies: Early trials and basic science. *Canadian Urological Association Journal*, **2013**, 7, S179-80	1.2	
49	New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. *Therapeutics and Clinical Risk Management*, **2013**, 9, 161-70	2.9	38
48	Therapeutic targets for premature ejaculation. *Maturitas*, **2011**, 70, 26-33	5	15
47	Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. *British Journal of Clinical Pharmacology*, **2011**, 72, 186-96	3.8	42
46	Antimuscarinic mechanisms and the overactive detrusor: an update. *European Urology*, **2011**, 59, 377-86	10.2	109
45	Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. *Neurourology and Urodynamics*, **2011**, 30, 292-301	2.3	162
44	Rodent models for urodynamic investigation. *Neurourology and Urodynamics*, **2011**, 30, 636-46	2.3	131
43	Drugs and future candidates. *Canadian Urological Association Journal*, **2011**, 5, S131-3	1.2	8

42	Studies of age-related impairments in regenerative capacity in adult mammals using the rodent bladder. *FASEB Journal*, **2011**, 25, 1087.13	0.9	
41	The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder. *BJU International*, **2010**, 106, 1114-27	5.6	78
40	Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. *Cell and Tissue Research*, **2010**, 342, 295-306	4.2	49
39	Words of wisdom. Re: Spontaneous release of acetylcholine from autonomic nerves in the bladder. *European Urology*, **2010**, 57, 171-2	10.2	2
38	Detrusor myocyte activity and afferent signaling. *Neurourology and Urodynamics*, **2010**, 29, 97-106	2.3	75
37	Maturation and growth of the bladder wall in a rodent model of organ regeneration. *FASEB Journal*, **2010**, 24, 754.1	0.9	
36	Prospective pharmacologic therapies for the overactive bladder. *Therapeutic Advances in Urology*, **2009**, 1, 71-83	3.2	34
35	The evolving physiology of the lower urinary tract: What we are learning and where we need to go. *Current Bladder Dysfunction Reports*, **2009**, 4, 81-85	0.4	
34	Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. *Current Opinion in Urology*, **2009**, 19, 380-94	2.8	143
33	Studies of tissue regeneration in a rat bladder model in vivo. *FASEB Journal*, **2009**, 23, 939.1	0.9	
32	Pharmacotherapy of the overactive bladder. *Discovery Medicine*, **2009**, 8, 118-24	2.5	22
31	Are female lower urinary tract symptoms alleviated by alpha-adrenoreceptor antagonists?. *Nature Reviews Urology*, **2008**, 5, 586-7		
30	Urothelial effects of oral agents for overactive bladder. *Current Urology Reports*, **2008**, 9, 459-64	2.9	16
29	What's hot from the ICS Annual Meeting 2006. *Neurourology and Urodynamics*, **2007**, 26, 148-153	2.3	
28	Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. *Neurourology and Urodynamics*, **2007**, 26, 928-33	2.3	62
27	Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. *BJU International*, **2007**, 100, 1007-14	5.6	22
26	Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. *Nature Reviews Urology*, **2007**, 4, 368-78		103
25	Regenerative pharmacology: the future is now. *Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics*, **2007**, 7, 79-86		12

24	Voiding patterns in uroplakin II knockout mice. *FASEB Journal*, **2007**, 21, A1301	0.9	
23	URODYNAMIC CHARACTERIZATION OF MICE LACKING UROPLAKIN II OR III. *FASEB Journal*, **2007**, 21, A1308	0.9	2
22	Threshold gene transfer with hSlo enhances sildenafil-induced erectile responses in 2 month streptozotocin(STZ)-diabetic rats. *FASEB Journal*, **2007**, 21, A420	0.9	
21	Urinary bladder contraction and relaxation: physiology and pathophysiology. *Physiological Reviews*, **2004**, 84, 935-86	47.9	658
20	Inhibitory effects of nitrendipine on myometrial and vascular smooth muscle in human pregnant uterus and placenta. *Acta Pharmacologica Et Toxicologica*, **1986**, 59, 1-10		48
19	Direct effects of adenosine and adenine nucleotides on isolated human urinary bladder and their influence on electrically induced contractions. *Journal of Urology*, **1983**, 130, 392-8	2.5	69
18	Atropine resistance of transmurally stimulated isolated human bladder muscle. *Journal of Urology*, **1982**, 128, 1368-71	2.5	232
17	Multichannel intrauterine pressure recording by means of microtransducers. *Acta Obstetricia Et Gynecologica Scandinavica*, **1979**, 58, 115-20	3.8	23
16	Uterine activity in diabetes insipidus. *Acta Obstetricia Et Gynecologica Scandinavica*, **1977**, 56, 381-5	3.8	4
15	The Past, Present, and Future of Tissue Regeneration311-328		
14	Stem and Progenitor Cells in Regenerative Pharmacology75-126		2
13	Incorporation of Active Factors (Pharmacological Substances) in Biomaterials for Tissue Engineering167-189		
12	Animal Models of Regenerative Medicine219-234		
11	Micro- and Nanoscale Delivery of Therapeutic Agents for Regenerative Therapy127-156		
10	Mechanical Control of Adult Mesenchymal Stem Cells in Cardiac Applications34-51		
9	Regenerative Pharmacology of the Bladder15-33		1
8	Gap JunctionMediated Therapies to Eliminate Cardiac Arrhythmias237-251		1
7	Kidney and Bladder Regeneration: Pharmacologic Methods52-72		

List of Publications

6 Introduction to Regenerative Pharmacology: A Short Primer on the Role of Pharmacological Sciences in Regenerative Medicine3-14

5 Bioreactor Technologies for Tissue Engineering a Replacement Heart Valve157-166

4 Enabling Drug Discovery Technologies for Regenerative Pharmacology190-218

3 Regenerative Cardiac Pharmacology: Translating Stem Cell Biology into Therapeutic Solutions252-269

2 Wound Healing and Cell Therapy for Muscle Repair270-289

1 Regenerative Pharmacology of Implanted Materials and Tissue-Engineered Constructs290-310